(2S,3R)-methyl 3-azido-2-(tritylamino)butanoate | 728877-99-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (2S,3R)-methyl 3-azido-2-(tritylamino)butanoate
• 英文别名: methyl (2S,3R)-3-azido-2-(tritylamino)butanoate
• CAS: 728877-99-4
• 化学式: C₂₄H₂₄N₄O₂
• 分子量: 400.48
• InChiKey: KIGTXIJSXOLEDD-GCJKJVERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  52.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,3R)-methyl 3-azido-2-(tritylamino)butanoate 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 反应 63.5h， 生成 (2S,3R)-2-amino-3-Fmoc-aminobutyric acid methyl ester hydrochloride
  参考文献：
  名称：

  Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC

  摘要：

  Over the past several decades, the frequency of antibacterial resistance in hospitals, including multidrug resistance (MDR) and its association with serious infectious diseases, has increased at alarming rates. Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all approved antibacterial agents is emerging in this pathogen. To address the need for new agents to treat MDR P. aeruginosa, we focused on inhibiting the first committed step in the biosynthesis of lipid A, the deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by the enzyme LpxC. We approached this through the design, synthesis, and biological evaluation of novel hydroxamic acid LpxC inhibitors, exemplified by 1, where cytotoxicity against mammalian cell lines was reduced, solubility and plasma-protein binding were improved while retaining potent anti-pseudomonal activity in vitro and in vivo.

  DOI：

  10.1021/acs.jmedchem.7b00377
• 作为产物：
  描述：

  三苯基甲基溴 在 叠氮磷酸二苯酯 、 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 24.0h， 生成 (2S,3R)-methyl 3-azido-2-(tritylamino)butanoate
  参考文献：
  名称：

  Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC

  摘要：

  Over the past several decades, the frequency of antibacterial resistance in hospitals, including multidrug resistance (MDR) and its association with serious infectious diseases, has increased at alarming rates. Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all approved antibacterial agents is emerging in this pathogen. To address the need for new agents to treat MDR P. aeruginosa, we focused on inhibiting the first committed step in the biosynthesis of lipid A, the deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by the enzyme LpxC. We approached this through the design, synthesis, and biological evaluation of novel hydroxamic acid LpxC inhibitors, exemplified by 1, where cytotoxicity against mammalian cell lines was reduced, solubility and plasma-protein binding were improved while retaining potent anti-pseudomonal activity in vitro and in vivo.

  DOI：

  10.1021/acs.jmedchem.7b00377

文献信息

• [EN] ORGANIC COMPOUNDS FOR APPLICATIONS IN BACTERIAL INFECTIONS TREATMENT<br/>[FR] COMPOSÉS ORGANIQUES DESTINÉS À ÊTRE APPLIQUÉS DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：NOVARTIS AG

  公开号：WO2010031750A1

  公开（公告）日：2010-03-25

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

  本申请描述了对治疗、预防及/or改善人类疾病的有机化合物。
• [EN] NOVEL COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSÉS ET LEUR UTILISATION
  申请人：DEBIOPHARM INT SA

  公开号：WO2021123372A1

  公开（公告）日：2021-06-24

  The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

  本发明提供了一般式（I）的化合物或其药用可接受的前药、盐和/或溶剂化合物，其中LHS选自LHSa和LHSb组成的组，星号（*）标记附着点；这些化合物对革兰氏阴性和革兰氏阳性细菌，特别是金黄色葡萄球菌、大肠杆菌、肺炎克雷伯菌和鲍曼不动杆菌表现出抗菌活性。还提供了含有这些化合物的药物组合物、其治疗用途和制备方法。
• [EN] UREA DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS D'URÉE EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：SCHERING CORP

  公开号：WO2010017060A1

  公开（公告）日：2010-02-11

  This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.

  这项发明涉及以下化合物的结构（I）：或其药用盐、溶剂合物、酯或异构体，用于治疗由LpxC介导的疾病或症状。
• Total Synthesis of Malacidin A by β‐Hydroxyaspartic Acid Ligation‐Mediated Cyclization and Absolute Structure Establishment
  作者：Zhenquan Sun、Zhuo Shang、Nicholas Forelli、Kathy Hiu Laam Po、Sheng Chen、Sean F. Brady、Xuechen Li

  DOI：10.1002/anie.202009092

  日期：2020.11.2

  action is distinct from classical CDAs. However, the absolute structure of malacidin A has not been established. Herein, the total syntheses of malacidin A and its analogues are reported by a combination of Fmoc‐based solid‐phase peptide synthesis (SPPS) and β‐hydroxyaspartic acid ligation‐mediated peptide cyclization. The total synthesis enabled us to establish the absolute configuration of malacidin

  新型抗生素的开发对于对抗日益增多的耐药病原体至关重要。Malacidin A 是钙依赖性抗生素 (CDA) 家族的新成员，具有抗抗生素耐药性病原体的活性。它的作用方式不同于经典的 CDA。然而，尚未确定马拉西丁 A 的绝对结构。在此，通过基于 Fmoc 的固相肽合成 (SPPS) 和 β-羟基天冬氨酸连接介导的肽环化的组合报道了 Malacidin A 及其类似物的全合成。全合成使我们能够建立马拉西丁 A 的绝对构型，这与我们研究中高级 Marfey 分析证实的天然马拉西丁 A 的构型一致。
• ANTIBACTERIAL AGENTS
  申请人：Andersen Niels H.

  公开号：US20080269221A1

  公开（公告）日：2008-10-30

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供化学式I的抗菌化合物：以及立体异构体，药学上可接受的盐，酯和前药; 包含这些化合物的制药组合物; 通过给予这些化合物的途径治疗细菌感染的方法; 以及制备这些化合物的工艺。